The ConNeCT Study: Neurological Complications of TTP

Last updated: August 2, 2021
Sponsor: Liverpool University Hospitals NHS Foundation Trust
Overall Status: Active - Recruiting

Phase

N/A

Condition

Thrombocytopenia And Thrombocytopenia Prevention

Platelet Disorders

Treatment

N/A

Clinical Study ID

NCT04981028
5988
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Thrombotic thrombocytopenic purpura (TTP) is a rare condition, which has a very high risk of death if not recognised and given immediate treatment. TTP is caused by a very low level of an enzyme in the body, called ADAMTS13. A lack of ADAMTS13 causes multiple small clots to form around the body which can disrupt the blood flow to important organs. Although survival has improved significantly, it is now being recognised that patients with TTP may suffer with longer term complications as a result of their condition; literature from the USA reports higher rates of major depression and also poor memory and reduced concentration in patients with TTP. The investigators aim to improve the understanding of the long-term complications and review, for the first time, forward-looking data at multiple time points in patients with TTP in the UK. Both patients with a new diagnosis and patients with a known diagnosis of TTP identified in NHS hospitals will be included, over a minimum duration of 2 years. This will be a questionnaire based study with both doctor led and participant led questionnaires at pre-determined points in time. By improving the understanding and comparing symptoms to that of the general population, the investigators hope to improve the support and tailor the treatments which can be offered to patients with TTP.

Eligibility Criteria

Inclusion

Inclusion Criteria:

1.Acute episode TTP:

  • Adult male or female patient ≥18 years of age at the time of signing the consent form,with a confirmed diagnosis of TTP (initial or relapse) based on ADAMTS13 <10% 2. Knowndiagnosis of TTP:
  • Adult male or female patient ≥ 18 years of age at time of signing the consent form,with a historical confirmed diagnosis of TTP (based on ADAMTS13 at initialpresentation <10%) 3. Healthy control:
  • Non-blood relative / friend / carer of patients under the care of Haematology clinicsat the Royal Liverpool University hospital or other participating centres.

Exclusion

Exclusion Criteria:

  1. Acute episode of TTP:
  • Participants less than 18 years old at the time of signing the consent form
  • Patient with ADAMTS13 greater than 10%
  • Patient with cancer or transplant associated MAHA will not be included
  • Patient (or NOK, where patient does not have capacity) not wishing to consent totrial
  1. Known diagnosis of TTP:
  • Participants less than 18 years old at the time of signing the consent form
  • Patient with ADAMTS13 greater than 10%
  • Patient with cancer or transplant associated MAHA will not be included
  • Patient (or NOK, where patient does not have capacity) not wishing to consent totrial
  1. For healthy control:
  • Participants less than 18 years old at the time of signing the consent form
  • Participant not wishing to consent to trial
  • Any personal or family history of thrombotic microangiopathy

Study Design

Total Participants: 250
Study Start date:
June 25, 2020
Estimated Completion Date:
June 25, 2022

Connect with a study center

  • Royal Liverpool University Hospital

    Liverpool,
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.